Dr. Victor Sloan, UCB’s VP & Development Strategy Lead (immunology), was featured in an interview as part of the Pharmaceutical Research and Manufacturers of America (PhRMA) #GOBOLDLY campaign. Learn more about Dr. Sloan’s work and his motivation to find groundbreaking solutions. 

UCB is passionate about transforming the lives of people living with severe diseases—whether through our current portfolio of medicines or our continued commitment to better uncovering the intersection of scientific understanding and patient needs. We continuously work to advance science and embrace new knowledge—leading to the discovery of unique outcomes that help specific patients achieve their goals. We are dedicated to research and development so our teams can find the right solution for the right patient at the right time. 
 

As UCB’s Vice President and Development Strategy Lead (within the Immunology Patient Value Unit), Dr. Sloan designs the framework for clinical trials and determines whether they are safe and effective for possible patients. He has worked in the field of rheumatology for over 20 years (and still volunteers his time to see patients), and throughout his career has played an active role in the remarkable progress in treatments for rheumatic diseases.  

Like many researchers, Dr. Sloan has a personal story—his late sister-in-law suffered from lupus for her entire adult life. The potential for finding groundbreaking and innovative solutions that can better the lives of those suffering from rheumatic diseases drives him each day. Dr. Sloan notes that although there has been tremendous progress in the journey to find new therapies, there are still more advancements to be made to solve for patients’ unmet needs – achieving the ultimate goal of helping patients live their best lives. 

Check back for more stories from UCB scientists.

Learn more about GOBOLDY.